BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34706602)

  • 1. NRG1 and NRG2 fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows.
    Trombetta D; Sparaneo A; Fabrizio FP; Di Micco CM; Rossi A; Muscarella LA
    Expert Opin Ther Targets; 2021 Oct; 25(10):865-875. PubMed ID: 34706602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
    Shin DH; Jo JY; Han JY
    Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Neuregulin 1 (NRG1): A Novel Biomarker for Non-Small-Cell Lung Cancer.
    Fang C; Kang B; Zhao P; Ran J; Wang L; Zhao L; Luo H; Tao L
    J Environ Pathol Toxicol Oncol; 2021; 40(4):61-72. PubMed ID: 34936301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NRG1-ErbB Lost in Translation: A New Paradigm for Lung Cancer?
    Trombetta D; Rossi A; Fabrizio FP; Sparaneo A; Graziano P; Fazio VM; Muscarella LA
    Curr Med Chem; 2017; 24(38):4213-4228. PubMed ID: 28901268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
    Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
    Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis.
    Nagasaka M; Ou SI
    Trends Cancer; 2022 Mar; 8(3):242-258. PubMed ID: 34996744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.
    Shin DH; Lee D; Hong DW; Hong SH; Hwang JA; Lee BI; You HJ; Lee GK; Kim IH; Lee YS; Han JY
    Oncotarget; 2016 Oct; 7(43):69450-69465. PubMed ID: 27626312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
    Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
    J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neuregulin-I/ErbB signaling system in development and disease.
    Britsch S
    Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities.
    Zhang C; Mei W; Zeng C
    Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188707. PubMed ID: 35247506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expert Consensus on the Diagnosis and Treatment of
    Xu C; Wang Q; Wang D; Wang W; Fang W; Li Z; Liu A; Yu J; Zhong W; Wang Z; Zhang Y; Liu J; Zhang S; Cai X; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Huang L; Pu X; Lin R; Liu W; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Zhang J; Xue J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Zhou J; Zhu Z; Li Y; Qiu H; Xia F; Lu Y; Chen X; Ge R; Dai E; Han Y; Pan W; Pang F; He Q; Huang J; Wang K; Wu F; Xu B; Wang L; Zhu Y; Lin L; Xie Y; Lin X; Cai J; Xu L; Li J; Jiao X; Li K; Wei J; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Huang J; Feng Y; Zhang Y; Sun P; Wang H; Ye M; Wang Z; Hao Y; Wang Z; Wan B; Lv D; Yang S; Kang J; Zhang J; Zhang C; Ou J; Shi L; Wang Y; Li B; Zhang Z; Li Z; Liu Z; Yang N; Wu L; Wang H; Jin G; Wang G; Wang J; Fang M; Fang Y; Li Y; Wang X; Zhang Y; Zhu X; Shen Y; Ma S; Wang B; Si L; Song Y; Lu Y; Chen J; Song Z
    Glob Med Genet; 2024 Jan; 11(1):86-99. PubMed ID: 38414979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization.
    Werr L; Plenker D; Dammert MA; Lorenz C; Brägelmann J; Tumbrink HL; Klein S; Schmitt A; Büttner R; Persigehl T; Shokat KM; Wunderlich FT; Schram AM; Peifer M; Sos ML; Reinhardt HC; Thomas RK
    Mol Cancer Ther; 2022 May; 21(5):821-830. PubMed ID: 35247925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer.
    Fernandez-Cuesta L; Thomas RK
    Clin Cancer Res; 2015 May; 21(9):1989-94. PubMed ID: 25501131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1.
    Shin DH; Kim SH; Choi M; Bae YK; Han C; Choi BK; Kim SS; Han JY
    Oncogene; 2022 Jan; 41(2):280-292. PubMed ID: 34743207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VAMP2-NRG1 Fusion Gene is a Novel Oncogenic Driver of Non-Small-Cell Lung Adenocarcinoma.
    Jung Y; Yong S; Kim P; Lee HY; Jung Y; Keum J; Lee S; Kim J; Kim J
    J Thorac Oncol; 2015 Jul; 10(7):1107-11. PubMed ID: 26134228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to ERBB3-Directed Targeted Therapy in
    Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
    Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
    [No Abstract]   [Full Text] [Related]  

  • 17. NRG1 fusions in breast cancer.
    Howarth KD; Mirza T; Cooke SL; Chin SF; Pole JC; Turro E; Eldridge MD; Garcia RM; Rueda OM; Boursnell C; Abraham JE; Caldas C; Edwards PAW
    Breast Cancer Res; 2021 Jan; 23(1):3. PubMed ID: 33413557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological Characteristics of NRG1 Fusion-Positive Solid Tumors in Korean Patients.
    Cha YJ; Lee C; Joo B; Kim KA; Lee CK; Shim HS
    Cancer Res Treat; 2023 Oct; 55(4):1087-1095. PubMed ID: 37321274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report.
    Nie X; Zhang P; Bie Z; Song C; Zhang M; Ma D; Cui D; Cheng G; Li H; Lei Y; Su X; Wu W; Li L
    World J Surg Oncol; 2023 Aug; 21(1):246. PubMed ID: 37587479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of NRG1 Gene Fusions in Solid Tumors.
    Jonna S; Feldman RA; Swensen J; Gatalica Z; Korn WM; Borghaei H; Ma PC; Nieva JJ; Spira AI; Vanderwalde AM; Wozniak AJ; Kim ES; Liu SV
    Clin Cancer Res; 2019 Aug; 25(16):4966-4972. PubMed ID: 30988082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.